



Memorandum

Date: December 5, 2011
To: Players, Tournaments, Coaches and Agents
CC: WTA Board of Directors, WTA Staff
From: Leah A. Rinfret, WTA Counsel
Subject: 2012 Tennis Anti-Doping Program

In 2012, the International Tennis Federation (ITF) will continue to control the management, administration and enforcement of the Tennis Anti-Doping Program (Program) at all WTA, ATP and ITF events. While the ITF is responsible for the overall management of the Program, the Program is a cooperative effort among the WTA, ATP and ITF.

International Doping Tests and Management (IDTM) will continue to serve as the Program testing services provider. Any questions relating to the Therapeutic Use Exemption (TUE) process should be directed to IDTM.

The current TUE and Product Information Request Forms are available on the PlayerZone (www.wta-playerzone.com) and the ITF Website (<http://www.itftennis.com/antidoping/tue/>).

2012 TENNIS ANTI-DOPING PROGRAM

This summary is only intended to highlight some of the key provisions and changes to the 2012 Program. It is not a substitute for a full review of the Program, which all players and player support personnel are strongly advised to do. The full Program is available on the WTA and ITF Websites and CD copies of the Program will be available on-site at the Australian tennis events and can be provided upon request.

Whereabouts Program

- **Testing Pool:** The 2012 International Registered Testing Pool (ITF Pool) is comprised of (i) the Top 50 Singles and Top 10 Doubles players based on the WTA Year-End Rankings and (ii) select members of the 2011 ITF Pool with WTA Year-End Singles rankings between 50-65. A complete list of the players included in the 2012 ITF Pool will be posted on the PlayerZone and ITF Website.
- **National Registered Testing Pools:** If a player is not in the ITF Pool but is in a national registered testing pool and is providing information about her whereabouts to her national anti-doping organization (NADO), the ITF is entitled to access and use her whereabouts information to find her for an out-of-competition test. If a player is not at her designated location, the ITF is responsible for processing the failed mission as a potential missed test.
- **ADAMS:** On November 23, WADA launched an improved module within the Anti-Doping Administration & Management System (ADAMS) that provides a more user-friendly and efficient Whereabouts interface for players to submit their whereabouts information. For a tutorial on ADAMS 3.0, visit their YouTube channel at <http://www.youtube.com/wadamovies>.

- Filing Whereabouts: For days when players are *Out-of-Competition*, they must include a 'daily residence' that provides the place where the player will be sleeping (i.e., hotel, home), as well as a 60-minute time slot and location between 6 AM and 11 PM every day where they will be accessible for testing. For players in the ITF Pool, they do not have to file any whereabouts information for days when they are *In-Competition* (i.e., from the day of their first match through the day of their last match), but it is recommended that players include the event name for days when they are *In-Competition*. When filing quarterly whereabouts, players can assume they will reach the final of every competition they enter and only file whereabouts for days between the final match and the start of the relevant draw in their next tournament. Players must update their whereabouts if they exit a tournament before the final match.
- ITF DCO Verification: For players in the ITF Pool being tested by the ITF, each ITF Doping Control Officer (DCO) must provide certain documentation and information which verifies who they are. These procedures have been put in place to ensure player safety. For more details on what information the DCO must provide, please refer to the 2012 Whereabouts Fact Sheet posted on the PlayerZone.
- **Reminders**: It is to a player's benefit to request an administrative review and raise all possible defenses to an alleged whereabouts failure prior to the failure being recorded against her. Players remain personally responsible for the information submitted on their behalf by another person.

Testing

- Notification Process: Refusing or failing to submit a sample after being notified of testing is an anti-doping violation; however, if a player was not properly notified of the testing, she may use the improper notification as a defense to a charge of refusing or failing to provide a sample.
- Failure to Comply with Testing: Players must make themselves familiar with the testing procedures set out in the International Standards for Testing (annexed to the Program), because a failure to comply with those requirements when tested either *In-* or *Out-of-Competition* (e.g., a failure to allow oneself to be chaperoned at all times while travelling to the doping control station) may amount to an anti-doping rule violation. A poster detailing players' rights and responsibilities during a sample collection will be posted on-site and can be found on the PlayerZone.
- Testing Samples: Due to the possible abuse of substances and methods that cannot be detected in urine analysis, WADA has placed greater emphasis on testing blood samples. In 2012, player test samples may include urine samples, blood samples or both. However, no blood samples will be taken while a player is *In-Competition* unless the test is collected after a player's last match, withdrawal, or default or if a player is a no-show at a tournament.

Investigations and Sanctions

- Whereabouts Violations Declared By Other Anti-Doping Organizations: Currently, the ITF reviews alleged whereabouts violations declared by other Anti-Doping Organizations against players in the ITF Pool. Language has been added to the Program for 2012 to ensure that it is clear to other Anti-Doping Organizations that the ITF will only recognize whereabouts violations against players in the ITF Pool if the ITF Review Board confirms that the alleged violation meets the requirements of the International Standard for Testing.
- Demand for Information: In an investigation of a suspected anti-doping rule violation, the ITF is allowed to ask a player suspected of the anti-doping violation for information by making a written demand to the player. To assist with the investigation process, the language in the Program has

been expanded to allow the ITF to ask a player who is not suspected of the anti-doping rule violation for information about a suspected anti-doping violation by making a written demand to such player.

- Provisional Suspensions - PST: Currently, the ITF has the discretion (not obligation) to impose a provisional suspension when a player has plead guilty to or otherwise admitted engaging in conduct that amounts to an anti-doping rule violation. This provision and the corresponding provisional suspension rules have been expanded to apply to player support team (PST) personnel as well.
- Presence at Hearings: WTA representatives will be permitted to attend an anti-doping rule violation hearing for a WTA ranked player as an observer.
- **Reminder**: Coaches, trainers, managers, agents, parents and any other person working with, treating or assisting a player must comply with the Program and a failure to comply may constitute an anti-doping violation and result in the denial of credentials and access to WTA, Grand Slam and ITF events.

TUEs and Changes to the WADA Prohibited List

- The use of pharmacological substances which are not approved by any governmental regulatory health authority for human use (i.e., discontinued drugs and drugs under pre-clinical or clinical development) and “designer drugs” (ie., a synthetic analogue of a restricted or prohibited drug with similar chemical structure and/or biologic effect) are prohibited at all times, regardless of whether or not they appear on the WADA Prohibited List.
- Formoterol has been removed from ‘Section 3 Beta-2 Agonists’ when taken by inhalation at therapeutic dosages. Therefore, the WADA Prohibited List prohibits the administration of all beta-2 agonists *except for* salbutamol (maximum 1600 micrograms over 24 hours), salmeterol when taken by inhalation, and now formoterol (maximum 36 micrograms taken over 24 hours).
- Bolandiol has been added to the list of prohibited Exogenous Anabolic Androgenic Steroids.
- Metabolites of DHEA have been added to the list of prohibited Endogenous Anabolic Androgenic Steroids.
- The following have been added to the list of prohibited metabolic modulators due to their re-categorization as substances that modify cellular metabolism: Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists (e.g. GW 1516), PPAR δ -AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR).
- The local application of felypressin in dental anesthesia is permitted.
- Catheterization has been removed as an example of a form of adulteration of samples collected during Doping Control. While it is still prohibited if used to tamper or attempt to tamper with the integrity of a sample collection, it is recognized that catheterization may be necessary for medical purposes.
- **TUE Reminder**: Players are responsible for knowing when their TUEs expire and submitting any TUEs granted by their NADO to the ITF for approval before playing a WTA event. In order to receive approval as quickly as possible, the TUE form must be properly completed by the physician. Contact the SS&M Department for assistance.

The full WADA Prohibited List is posted on the PlayerZone. The 2012 Walletcard is also available on-site via a Player Relations or SS&M staff member and on the ITF Website and PlayerZone. These documents should be provided to treating physicians.

CONTACTS

For questions regarding any specific substances, medications, and TUEs, contact:

International Doping Tests & Management (IDTM)

Phone: +46 8 555 10 999

Fax: +46 8 555 10 995

E-mail: tennis@idtm.se

Website: www.idtm.se

For questions regarding the Program, including Whereabouts filing requirements, contact:

International Tennis Federation (ITF)

Attn: Whereabouts Coordinator

Phone: +44 20 8392 4658

Fax: +44 20 8392 4696

Email: anti-doping@itftennis.com

In the event of a conflict between the English version and a translated version, the English version controls.